ArticleSubstance abuse treatment, prevention, and policy2013
A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada.
Article in Substance abuse treatment, prevention, and policy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American Cities: A Systematic Review.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2024Pooled it
- Pooled it
- Pooled it
- County by county estimation of possible deaths averted, infections averted, and cost savings of overdose prevention centers in the United States from July 2019-June 2025.The International journal on drug policy · 2026Article
- County by county estimation of possible deaths averted, infections averted, and cost savings of overdose prevention centers in the United States from July 2019-June 2025.medRxiv : the preprint server for health sciences · 2026Article
- Saskatoon, Saskatchewan's safe consumption site provides a sizeable social and economic return on investment.Frontiers in public health · 2026Article
- Economic evaluation of the effect of needle and syringe programs on skin, soft tissue, and vascular infections in people who inject drugs: a microsimulation modelling approach.Harm reduction journal · 2024Article
- Cost-effectiveness of drug consumption rooms in France: a modelling study.BMC public health · 2024Article
- Article
- Factors associated with injury and blood-borne infection risk when providing assisted injection among people who inject drugs.The International journal on drug policy · 2021Article
- Feasibility, acceptability, concerns, and challenges of implementing supervised injection services at a specialty HIV hospital in Toronto, Canada: perspectives of people living with HIV.BMC public health · 2021Article
- Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach.Journal of market access & health policy · 2021Article
- Acceptability of safe drug consumption spaces among people who inject drugs in rural West Virginia.Harm reduction journal · 2019Article
- Expanding supervised injection facilities across Canada: lessons from the Vancouver experience.Canadian journal of public health = Revue canadienne de sante publique · 2018Article
- Use of on-site detoxification services co-located with a supervised injection facility.Journal of substance abuse treatment · 2017Article
- Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility.Harm reduction journal · 2017Article
- Willingness to use a supervised injection facility among young adults who use prescription opioids non-medically: a cross-sectional study.Harm reduction journal · 2017Article
- Article
- Examining the potential role of a supervised injection facility in Saskatoon, Saskatchewan, to avert HIV among people who inject drugs.International journal of health policy and management · 2015Article
- A cost-benefit/cost-effectiveness analysis of an unsanctioned supervised smoking facility in the Downtown Eastside of Vancouver, Canada.Harm reduction journal · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis paper will determine whether expanding Insite (North America's first and only supervised injection facility) to more locations in Canada such as Montreal, cost less than the health care consequences of not having such expanded programs for injection drug users.
methodsBy analyzing secondary data gathered in 2012, this paper relies on mathematical models to estimate the number of new HIV and Hepatitis C (HCV) infections prevented as a result of additional SIF locations in Montreal.
resultsWith very conservative estimates, it is predicted that the addition of each supervised injection facility (up-to a maximum of three) in Montreal will on average prevent 11 cases of HIV and 65 cases of HCV each year. As a result, there is a net cost saving of CDN$0.686 million (HIV) and CDN$0.8 million (HCV) for each additional supervised injection site each year. This translates into a net average benefit-cost ratio of 1.21: 1 for both HIV and HCV.
conclusionsFunding supervised injection facilities in Montreal appears to be an efficient and effective use of financial resources in the public health domain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.